T-DXd vs T-DM1 in HER2+ Early BC

DESTINY-Breast05 (NCT04622319), presented by Dr. Charles E. Geyer (Pittsburgh, United States of America) at the ESMO Congress 2025, is a pivotal phase 3, open-label, randomized trial evaluating trastuzumab deruxtecan (T-DXd)…